Topical application of beneficial lactobacilli and potentially other ‘live biotherapeutic products’ (LBPs) show great potential as an alternative strategy to tackle Skin care problems related to disturbance of the skin microbiome, providing alternatives to the overuse of antibiotics in skin care.
Microbiome Times caught up with Dr Ingmar Claes, CSO of YUN, a Belgian biotech company spun-out from the University of Antwerp to learn more about how they are developing LBPs to treat skin conditions.
Here is an extract:
While there has been much debate on what constitutes a healthy microbiome, it is clear that it is all a matter of balance. Differences in the skin microbiome composition, either in diversity (alpha and beta diversity between body sites) and in the specific taxonomics strains present exist between individuals and skin locations. However, we now know which typical genera are present on the human skin based on the body site and whether it is dry, moist or sebaceous. Taking acne vulgaris as an example, it is specific Cutibacterium spp. (formerly known as Propionibacterium acnes) and also Staphylococci that play an important role in the pathophysiology of acne, the induction of inflammation and the formation of papules and pustules, i.e. ‘pimples’
To read the article, go to: http://www.microbiometimes.com/biotech-focus-live-lactobacilli-as-a-solution-to-improve-skin-health/
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology